Statins and Endometrial Cancer: What Does the Latest Research Say?
"A comprehensive meta-analysis explores the connection between statin use and endometrial cancer risk, offering insights for women's health."
Endometrial cancer is the most prevalent gynecologic malignancy in the United States, with projections estimating 60,050 new cases in 2016 alone. While obesity is a well-established risk factor, the connections between endometrial cancer and related conditions like hypertension and dyslipidemia remain less clear. Given the challenges of advanced-stage endometrial cancer, it's crucial to identify factors that could help reduce risk.
Statins, also known as 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are widely prescribed to lower cholesterol levels and prevent cardiovascular disease. These medications work by blocking HMG-CoA reductase, an enzyme vital for converting HMG-CoA into mevalonic acid, a precursor to cholesterol. This process is thought to trigger significant changes in cellular functions by affecting the mevalonic acid pathway.
The relationship between statin use and cancer risk has been a topic of ongoing debate. Some studies in rodents have suggested a link between lipid-lowering drugs, including statins, and an increased incidence of cancer. However, other research indicates that statins may suppress cell proliferation, induce apoptosis, inhibit angiogenesis, and prevent metastasis—all factors that could potentially prevent cancer growth and development. Given these conflicting findings, a new meta-analysis was undertaken to clarify the impact of statins on endometrial cancer risk.
Standard Treatment and Evidence Gaps
Surgical intervention is a standard treatment for endometrial cancer, and the cited review describes total hysterectomy as the recommended surgical treatment. The review notes that surgery can have substantial adverse effects and that the need for nonsurgical options is pressing. A 2026 review reports that statins have not been rigorously tested in prospective trials for gynecologic cancers; existing evidence is largely observational and heterogeneous, with concerns including confounding by indication, immortal time bias, and inconsistent adjustment for clinical covariates.
Do Statins Really Affect Endometrial Cancer Risk? A Meta-Analysis Breakdown
A meta-analysis was conducted, examining data from both randomized controlled trials (RCTs) and non-randomized studies, to evaluate the effect of statins on endometrial cancer risk. Researchers conducted a comprehensive search of electronic databases, conference abstracts, and clinical trial registers to gather both published and unpublished results. Studies that evaluated exposure to statins and endometrial cancer risk were considered for inclusion.
- Study Selection: The meta-analysis included two RCTs and eleven non-randomized studies, comprising four cohort studies and seven case-control studies. These studies involved a total of 9,517 cases of endometrial cancer.
- Key Finding: The analysis revealed no significant association between statin use and endometrial cancer risk. This was consistent across both RCTs (RR, 0.72; 95% CI, 0.19 to 2.67) and non-randomized studies (RR, 0.94; 95% CI, 0.82 to 1.07). A combined analysis of all included studies also confirmed that statin use did not significantly affect endometrial cancer risk (RR, 0.94; 95% CI, 0.82 to 1.07).
- Sensitivity Analysis: A sensitivity analysis was performed to assess the stability of the results. This analysis confirmed that the findings were robust and not significantly influenced by any single study.
Mixed Findings Across Cancer Sites
A 2026 mapping study of statin–cancer research reports that several analyses found no association between statin use and endometrial cancer incidence, highlighting that findings vary by cancer site. A meta-analysis involving 9,517 endometrial cancer patients likewise found inadequate evidence for an association between statin use and endometrial cancer risk. By contrast, a broad review of pooled meta-analyses reports lower likelihoods for several cancer groups, including gynecological cancers, but its supplied summary does not establish an endometrial-cancer-specific reduction.
Meta-Analysis Finds No Clear Risk Association
A 2017 meta-analysis found that the association between statin use and endometrial cancer risk was not statistically significant in studies from North America (6 studies; RR 0.97, 95% CI 0.78–1.20) or Europe (4 studies; RR 1.04, 95% CI 0.97–1.11). The analysis included randomized controlled trials and non-randomized studies, drawing on searches of databases, conference abstracts, and clinical-trial registers. These regional results do not show a statistically significant association, while the broader relationship between statin use and endometrial cancer risk has been described as controversial.
Preclinical Promise, Uncertain Clinical Evidence
A 2026 review describes statins as having antineoplastic activity in preclinical models but says their clinical efficacy in gynecologic malignancies remains uncertain. A 2023 review reports that any reduction in endometrial cancer risk among statin users is likely attributable to mechanisms other than lowering LDL cholesterol, or may offset an unexplained inverse association between genetically predicted LDL-cholesterol levels and endometrial cancer risk. The 2019 meta-analysis also characterizes the relationship between statin use and ovarian or endometrial cancer risk as controversial.
What Does This Mean for Statin Users?
The current meta-analysis suggests that statins don't significantly impact endometrial cancer risk. However, due to limitations in the available data, including the limited number of relevant RCTs and variations in study designs, further high-quality clinical studies are needed to validate these findings. If you have concerns about endometrial cancer risk or statin use, consult with your healthcare provider for personalized advice based on your individual health profile. Understanding your risk factors and discussing them with your doctor is key to making informed decisions about your health.
Evidence Remains Controversial
A 2019 meta-analysis examined the relationship between statin use and ovarian and endometrial cancer risk using original comparative studies retrieved from PubMed, Embase, and Web of Science. Its authors describe the relationship as controversial. The supplied source summary does not establish a definitive effect of statins on endometrial cancer risk.